New drug hopes to boost Radiation's punch against tough gut cancers
NCT ID NCT02381561
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The goal is to find the safest dose and see if it can make radiation therapy more effective at shrinking tumors. Nineteen participants with cancers of the esophagus, stomach, liver, pancreas, or bowel are enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILE DUCT CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Can artificial intelligence think like a cancer tumor board?
- A new clue in the fight against colorectal cancer recurrence?
- Can radiation plus immunotherapy make colon tumors disappear before surgery?
- Can a chemo boost outsmart lingering colon cancer cells?
- Does practice make perfect? a study probes how a Surgeon's learning curve impacts cancer surgery success